The effect of losartan and captopril on glomerular basement membrane anionic charge in a diabetic rat model

Journal of Hypertension

Volumn 17, Issue 8, 1999, Pages 1217-1223

  Yavuz, Dilek G ^a,c   Ersöz, Önder ^a   Kuçükkaya, Belgin ^a   Budak, Yasemin ^b   Ahiskali, Rengin ^a   Ekicioǧlu, Gülsün ^a   Emerk, Kaya ^a   Akalin, Sema ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b Hipokrat Research Laboratories   (Turkey)

^c Sakizgülü sok   (Turkey)

Author keywords

Albuminuria; Captopril; Diabetes; Erythrocyte membrane charge; Glomerular anionic charge; Glycosaminoglycan; Losartan; Rat

Indexed keywords

ALBUMIN; CAPTOPRIL; CREATININE; DRINKING WATER; GLYCOSAMINOGLYCAN; LOSARTAN; SIALIC ACID; STREPTOZOCIN; TAP WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETOGENESIS; DRUG EFFECT; FEEDING; FEMALE; GLOMERULUS BASEMENT MEMBRANE; MEMBRANE CURRENT; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; URINE LEVEL;

EID: 0032769592     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917080-00023     Document Type: Article

References (44)

1. 1 Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin dependent diabetes mellitus. Kidney Int 1988; 33:100-106.
2. 2 Banstad HJ, Kofoed-Enevoldsen A, Dahl-Jorgensen K, Hanssen KF. Glomerular charge selectivity and the influence of improved blood glucose control in type I (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1992; 35:1165-1169.
3. 3 Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreansen HB, Feldt-Rasmussen B. Size and charge selectivity of glomerular filtration in type I (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36:244-251.
4. 4 Noth RH, Krolewski AS, Kayson GA, Mayer TW, Schambelan M. Diabetic nephropathy: hemodynamic basis and implications for disease management. Ann Intern Med 1989; 110:795-813.
5. 5 Striker GE, Eastman RD, Striker LJ. Diabetic nephropathy: molecular analysis of extracellular matrix and clinical studies update. Nephrol Dial Transplant 1996; 11(suppl 5):58-61.
6. 6 Walker JD, Close CF, Jones SL, Rafftery M, Keen H, Viberti G, et al. Glomerular structure in type I (insulin-dependent) diabetic patients with normo-and microalbuminuria. Kidney Int 1992; 41:741-748.
7. 7 Scandling JD, Myers BO. Glomerular size selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992; 41:840-846.
8. 8 Osterby R, Brekke IB, Gundersen HJ, Jorgensen HE, Lokkegaard H, Mogensen CE, et al. Quantitative studies of glomerular ultrastructure in human and experimental diabetes. Appl Pathol 1984; 2:205-211.
9. 9 Morano S, Pietravalle P, De Rossi MG, Mariani G, Cristina G, Medici F, et al. A charge selectivity impairment in protein permselectivity is present in type 2 diabetes. Acta Diabetol 1993; 30:138-142.
10. 10 Kverneland A, Feld-Rasmussen B, Vidal P, Welinder B, Bent-Hansen L, Soegaard U, et al. Evidence of changes in renal charge selectivity in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1986; 29:634-639.
11. 11 Kasiske BL, Kalil RS, Ma JZ ,Liao M ,Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-138.
12. 12 Viberti GL, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbumiuria. JAMA 1994; 271:275-279.
13. 13 Hommel E, Parving HH, Mathiesen E, Edsberg B, Damkjaer NM, Giese J. Effect of captopril on kidney function in insulin dependent diabetic patients with nephropathy. BMJ 1986; 293:467-470.
14. 14 Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989; 32:326-328.
15. 15 Myers BD, Meyer TW. Angiotensin-converting enzyme inhibitors in the treatment of diabetic glomerulopathy. Nephron 1990; 55 (suppl 1):27-29.
16. 16 Marre M, Chatellier G, Leblanc H, Guyene TT, Menard J, Passa P. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297:1092-1095.
17. 17 Mathiesen ER, Hommel E, Giese J, Parving HH. Eficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303:81-87.
18. 18 Laffel LMB, McGill JB, Gans DJ, North America Microalbuminuria Study group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99:497-504.
19. 19 Reddi AS. Prevention of albuminuria by captopril in diabetic rats. Gen Pharmacol 1991; 22:323-328.
20. 20 Reddi AS, Ramamurthi R, Miller M, Dhuper S, Lasker N. Enalapril improves albuminuria by preventing glomerular loss of heparan sulfate in diabetic rats. Biochem Med Metab Biol 1991; 45:119-131.
21. 21 Hansen PM, Mathiesen ER, Kofoed-Enevoldsen A, Deckert T. Possible effect of angiotensin converting enzyme inhibition on glomerular charge selectivity. J Diabetes Compl 1995; 9:158-162.
22. 22 Rosenthal T, Erlich Y, Rossenmann E, Cohen A. Effects of enalpril, losartan and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension 1997; 29:1260-1264.
23. 23 Remmuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, et al. Short-and long term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4:40-49.
24. 24 Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant 1997; 12:640-642.
25. 25 Ichikawa I. Will angiotensin II receptor antagonist be renoprotective in humans? Kidney Int 1996; 50:684-692.
26. 26 Gambaro G, Baggio B, Cicerello E, Mastrosimone S, Marzaro G, Bosatti A, et al. Abnormal erythrocyte charge in diabetes mellitus. Link with microalbuminuria. Diabetes 1988; 37:745-748.
27. 27 Yokoyama H, Jensen JS, Myrup B, Mathiesen ER, Ronn B, Deckert T. Raised serum sialic concentration precedes onset of microalbuminuria in IDDM. A 10-year follow-up study. Diabetes Care 1996; 19:435-440.
28. 28 McAuliffe AV, Fisher EJ, McLennan SV, Yue DK, Turtle JR. Urinary glycosaminoglycan excretion in NIDDM subjects. Its relationship to albuminuria. Diabetic Med 1996; 13:758-763.
29. 29 Sweet CS, Nelson EB. How well have animal studies with losartan predicted responses in humans? J Hypertens 1993; 11:S63-S67.
30. 30 Levin M, Smith C, Walters MDS, Gascoine P, Barratt TM. Steroid-responsive nephrotic syndrome: a generalised disorder of membrane negative charge. Lancet 1985; ii:239-242.
31. 31 Beutler E, West C, Blume KG. The removal of leucocytes and platelets from whole blood. J Lab Clin Med 1976; 88:328-333.
32. 32 Jong JGN, Wavera RA, Laarakkers C, Poorthula BJHM. Dimethylene blue based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccaridosis. Clin Chem 1989; 35:1472-1477.
33. 33 Crook M, Haq M, Tutt P. Evaluation of three assays for the determination of serum sialic acid. Clin Biochem 1993; 26:449-454.
34. 34 Schumacher U, Adam E. Standardization of staining in glycosaminoglycan histochemistry: Alcian blue, its analogues and diamine methods. Biotech Histochem 1994; 69:18-24.
35. 35 Yatsumoto T, Naitoh T, Shikada K, Tanaka S. Effects of specific antagonists of angiotensin II receptors and captopril in diabetic nephropathy in mice. Jpn J Pharmacol 1997; 75:59-64.
36. 36 Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, et al. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995; 13:97-103.
37. 37 Nakamura Y, Myers B. Charge selectivity of proteinuria in diabetic glomerulopathy. Diabetes 1988; 37:1202-1211.
38. 38 Chen J, Gall MA, Yokoyama H, Jensen JS, Decket M, Parving HH. Raised serum sialic acid concentration in NIDDM patients with and without diabetic nephropathy. Diabetes Care 1996; 19:130-134.
39. 39 Crook MA, Tutt P, Pickup JC. Elavated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care 1993; 16:57-60.
40. 40 Powrie JK, Watts GF, Crook MA, Ingram JN, Taub NA, Shaw KM. Serum sialic acid and the long term complications of insulin dependent diabetes mellitus. Diabetes Med 1996; 13:238-242.
41. 41 Gansevoort RT, de Zeeuw D, Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45:861-867.
42. 42 Fenoy FJ, Scicli G, Carretero O, Roman RJ, Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991; 17:1038-1044.
43. 43 Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates cyclic guanosine 3,5-monophosphate and AT1 receptor mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996; 97:1978-1982.
44. 44 Maeso R, Navairo-Cid J, Munoz-Garcia R, Rodrigo E, Ruilope LM, Lahera V, et al. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats: role of nitric oxide and angiotensin II type 2 receptors. Hypertension 1996; 28:967-972.